Velocity Clinical Research, Waco

The trials here

What the 11 trials at this site are about, from their registry records.

Conditions

• Obesity5 trials
• Fatty liver disease (MASLD/MASH)4 trials
• Type 2 diabetes2 trials
• Chronic kidney disease1 trial
• High blood pressure1 trial
• Liver cirrhosis1 trial
• Lupus (SLE)1 trial
• Osteoarthritis1 trial
• Sjögren's disease1 trial

Phase

• Phase 38 trials
• Phase 22 trials
• Phase 2/31 trial

Status

• Recruiting5 trials
• Completed3 trials
• Active, not recruiting2 trials
• Not yet recruiting1 trial

Lead sponsor

• Boehringer Ingelheim5 trials
• Biogen1 trial
• Eli Lilly and Company1 trial
• GlaxoSmithKline1 trial
• Housey Healthcare ULC1 trial
• and 2 more

Running trials

• Recruiting

  A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)

  NCT07919678· Phase 3· Pfizer· Source

• Recruiting

  Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease

  NCT07404865· Phase 3· Vor Biopharma· Source

  Contact: Jeremy Sokolove

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Recruiting

  LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

  NCT06632457· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Recruiting

  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Recruiting

  HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes

  NCT07546929· Phase 2· Housey Healthcare ULC· Source

  Contact: Gregg Lucksinger, MD (principal investigator)

• Active, not recruiting

  A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

  NCT05556512· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

  NCT05531565· Phase 2/3· Biogen· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fatty liver disease (MASLD/MASH)2 recruiting
• Type 2 diabetes2 recruiting
• High blood pressure1 recruiting
• Liver cirrhosis1 recruiting
• Obesity1 recruiting
• Osteoarthritis1 recruiting
• Sjögren's disease1 recruiting

Closed trials

• Completed

  A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)

  NCT06309992· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension

  NCT04880031· Phase 2· GlaxoSmithKline· Source